Cannabis Stock Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) Soars on Acquisition
Aurora Cannabis (ACB) shares rose over 20% on both TSX and Nasdaq after announcing its acquisition by Organigram (OGI) for C$7.80 per share, a 93% premium over its unaffected price. The deal, valued at approximately C$561 million, offers Aurora shareholders cash, Organigram shares, or a combination. The combined company aims to expand globally, leveraging both firms' strengths in medical and recreational cannabis markets.
How this was made
The 30-second read
Why it matters
The disclosed offer price and stated premiums to Aurora’s unaffected price and the Curaleaf hostile bid are immediate valuation inputs for ACB and can drive merger-arb positioning.
Market read
This is a same-day, deal-premium catalyst for ACB, with traders likely focusing on deal certainty and merger-arbitrage spreads.
What to watch
The article does not detail regulatory timing, antitrust review, or financing structure for the acquirer, which are key determinants of deal spread and downside risk.
Background
Aurora and Organigram entered an arrangement agreement for Organigram to acquire all outstanding Aurora shares at C$7.80, following Aurora’s rejection of a Curaleaf hostile bid.
Ticker impact
Aurora Cannabis agreed to be acquired by Organigram at C$7.80 per share, driving a reported ~20% jump in ACB trading.
Likely upward pressure as traders price the announced offer premium and deal probability, with volatility around deal terms and regulatory/closing conditions.
The article is centered on the announced acquisition arrangement agreement and cites the offer price and premiums, which are direct drivers of near-term valuation and trading.
Market effects
Signals continued consolidation in Canadian and European cannabis, potentially repricing takeover expectations for other cash-constrained peers.
Could lift sentiment for Canada-listed cannabis names and increase M&A activity expectations in Europe-linked medical cannabis supply chains.
Deal framing around EU-GMP capacity and international footprint may influence cross-border competitive positioning narratives for global cannabis operators.
Counterpoint
Announced deal terms can still face regulatory, financing, or shareholder approval hurdles, so the stock can retrace if deal certainty deteriorates.
Key entities
- acquirer_targetAurora Cannabis Inc.
Subject of the acquisition arrangement agreement, receiving C$7.80 per share consideration options.
- acquirerOrganigram Global Inc.
Announced it will acquire all issued and outstanding Aurora shares under the arrangement agreement.
- third_party_bidderCuraleaf Holdings, Inc.
Referenced as having launched an unsolicited hostile bid that Aurora’s board rejected.
